Header Logo

Connection

Karen Wernli to Tamoxifen

This is a "connection" page, showing publications Karen Wernli has written about Tamoxifen.
Connection Strength

0.053
  1. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. J Clin Oncol. 2023 Feb 01; 41(4):859-870.
    View in: PubMed
    Score: 0.053

© 2024 Kaiser Permanente